Sanofi receives SEC recommendation to bring new therapies of Pompe, ASMD to India
The company hopes to launch these therapies in India by end of 2023 or beginning of next year, subject to completion of all…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Pompe disease
US FDA approves Nexviazyme for late-onset Pompe disease
The approval is based on the positive phase-III data demonstrating improvements in key disease burden measures and establishing…
EMA to review MAA for avalglucosidase alfa, enzyme replacement therapy to treat Pompe disease
The MHRA in the UK has granted Promising Innovative Medicine designation for avalglucosidase and US FDA has granted it…
Rare Diseases: Awaiting renewed focus
India needs to make significant investments in R&D, policy reforms, and measures to enable affordability and accessibility of…